NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,231 | -58.7% | 1,150 | 0.0% | 0.00% | – |
Q2 2023 | $2,979 | +59480.0% | 1,150 | -6.0% | 0.00% | – |
Q1 2023 | $5 | -66.7% | 1,224 | -58.6% | 0.00% | – |
Q4 2022 | $15 | -99.8% | 2,953 | +156.8% | 0.00% | – |
Q3 2022 | $6,000 | -70.0% | 1,150 | -24.5% | 0.00% | – |
Q2 2022 | $20,000 | +233.3% | 1,524 | +307.5% | 0.00% | – |
Q1 2022 | $6,000 | -94.5% | 374 | -94.6% | 0.00% | -100.0% |
Q4 2021 | $109,000 | +78.7% | 6,921 | +139.6% | 0.00% | – |
Q3 2021 | $61,000 | -69.3% | 2,889 | -71.4% | 0.00% | -100.0% |
Q2 2021 | $199,000 | -15.3% | 10,099 | +24.7% | 0.00% | 0.0% |
Q1 2021 | $235,000 | -4.1% | 8,099 | 0.0% | 0.00% | -50.0% |
Q4 2020 | $245,000 | +421.3% | 8,099 | +175.3% | 0.00% | – |
Q3 2020 | $47,000 | -60.8% | 2,942 | -51.7% | 0.00% | -100.0% |
Q2 2020 | $120,000 | +66.7% | 6,091 | +3.9% | 0.00% | 0.0% |
Q1 2020 | $72,000 | -33.3% | 5,863 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $108,000 | +33.3% | 5,863 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $81,000 | – | 5,863 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Column Group LLC | 18,136,735 | $237,228,000 | 52.50% |
Ponoi II Management, LLC | 1,298,908 | $16,990,000 | 44.41% |
Ponoi Management, LLC | 1,298,908 | $16,990,000 | 23.20% |
Euclidean Capital LLC | 746,674 | $9,766,000 | 9.07% |
StepStone Group LP | 1,573,357 | $20,580,000 | 2.93% |
Logos Global Management LP | 850,000 | $11,118,000 | 1.37% |
First Light Asset Management, LLC | 955,505 | $12,498,000 | 1.26% |
GREAT POINT PARTNERS LLC | 316,256 | $4,137,000 | 1.00% |
Rubric Capital Management LP | 877,161 | $11,473,000 | 0.58% |
Avidity Partners Management LP | 1,798,100 | $23,519,000 | 0.48% |